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http://www.translational-medicine.com/content/12/1/257RESEARCH Open AccessThe prognostic significance of RUNX2 and
miR-10a/10b and their inter-relationship in
breast cancer
Chih-Hao Chang1,2, Tan-Chi Fan2, Jyh-Cherng Yu3, Guo-Shiou Liao3, You-Chin Lin4, Arthur Chun-Chieh Shih5†,
Wen-Hsiung Li1,6,7*† and Alice Lin-Tsing Yu1,2,8*†Abstract
Background: The major cancer related mortality is caused by metastasis and invasion. It is important to identify
genes regulating metastasis and invasion in order to curtail metastatic spread of cancer cells.
Methods: This study investigated the association between RUNX2 and miR-10a/miR-10b and the risk of breast
cancer relapse. Expression levels of RUNX2 and miR-10a/b in108 pairs of tumor and non-tumor tissue of breast
cancer were assayed by quantitative PCR analysis and evaluated for their prognostic implications.
Results: The median expression levels of RUNX2 and miR-10b in tumor tissue normalized using adjacent non-tumor
tissue were significantly higher in relapsed patients than in relapse-free patients. Higher expression of these three genes
were significantly correlated with the hazard ratio for breast cancer recurrence (RUNX2: 3.02, 95% CI = 1.50 ~ 6.07;
miR-10a: 2.31, 95% CI = 1.00 ~ 5.32; miR-10b: 3.96, 95% CI = 1.21 ~ 12.98). The joint effect of higher expression of all
three genes was associated with a hazard ratio of 12.37 (95% CI = 1.62 ~ 94.55) for relapse. In a breast cancer cell line,
RUNX2 silencing reduced the expression of miR-10a/b and also impaired cell motility, while RUNX2 overexpression
elicited opposite effects.
Conclusions: These findings indicate that higher expression of RUNX2 and miR-10a/b was associated with adverse
outcome of breast cancer. Expression levels of RUNX2 and miR-10a/b individually or jointly are potential prognostic
factors for predicting breast cancer recurrence. Data from in vitro studies support the notion that RUNX2 promoted cell
motility by upregulating miR-10a/b.
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Breast cancer is the most common malignant disease in
women. Approximately 10 ~ 15% breast cancer patients
have an aggressive disease and develop distant metastases
[1] to bone, lung, liver and brain [2]. Up to 70% of bone
metastases occur in advanced breast cancer patients [3].
Moreover, five year survivability for breast cancer patients
with bone metastasis is only 20% after its detection [4].* Correspondence: whli@gate.sinica.edu.tw; aliceyu@ucsd.edu
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unless otherwise stated.Runt-related transcription factor 2 (RUNX2) has been
shown to play an important role in osteogenesis and de-
velopment of osteosarcoma [5]. Runx2 was also re-
ported to be highly expressed in breast cancer with
poor clinical outcomes [6]. Recently, McDonald et al.
showed that high RUNX2 expression is significantly
associated with estrogen receptor (ER)/progesterone
receptor (PR)/HER2-negative breast cancers and that
patients with high RUNX2 expression have a poorer
survival rate than those with negative or low expression
[7]. Moreover, in non-small cell lung cancer-patients,
higher RUNX2 expression was significantly correlated
with tumor progression and metastasis [8]. In epithelial
ovarian cancer, various genes involved in tumor invasion
and metastasis were suppressed upon RUNX2 knockdownLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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genes involved in bone invasion, such as MMPs, VEGF,
OP, and BSP, by RUNX2, suggesting that this master
transcription factor might contribute to bone metastasis
in breast tumor [10-13]. This is consistent with the report
that RUNX2 silencing reduced cell motility of metastatic
breast cancer cell line, MDA-MB-231. On the other hand,
RUNX2 overexpression increased cell migration ability in
non-metastatic MCF7 breast cancer cell line [14].
MicroRNAs (miRNAs), a group of ~22 nucleotides
endogenous and evolutionarily conserved single-stranded
small non-coding RNAs, are crucial post-transcriptional
regulators of a variety of biological processes, including the
initiation, progression and metastases of cancer [15-18]. As
reported in several studies, the miRNA-10 (miR-10) family,
including miR-10a and miR-10b which are identical except
for the 12th nucleotide [19], play an important role in
tumorigenesis and progression [20,21]. MiR-10a was
reported to be downregulated in chronic myeloid leukaemia
and acute myeloid leukaemia, and upregulated in colon
cancer and hepatocellular carcinomas [20]. Mir-10a was
also reported to gain in copy number in melanoma and
breast cancer [22] and overexpression of miR-10a
promoted cell migration and invasion of hepatoma
cancer cell lines [23] and cervical cancer cell lines in vitro
[24]. On the other hand, miR-10b was upregulated in pan-
creatic cancer and B-cell chronic lymphocytic leukemia
[20] In addition, miR-10b was highly expressed in breast
tumor with poor clinical outcomes [25] and facilitated cell
migration and invasion in breast cancer [26].
These findings suggest that RUNX2 and miR-10a/b
play important role in progression and metastases in
breast cancer, but the association between RUNX2 and
miR-10a/b, if any, is unknown. In this study, we try to
decipher the relationship between RUNX2 and miR-10a/b
in clinical breast cancer samples as well as in cell lines. We
demonstrated that expression of RUNX2 significantly
correlated with miR-10a/b in ER negative and triple
negative breast cancers and the expression levels of
RUNX2 and miR-10a/b individually or jointly were
significant prognostic factors for predicting breast
cancer recurrence. Furthermore, RUNX2 silencing in
MDA-MB-231 cells downregulated miR-10a/b transcription
and clearly impeded cell motility. These results indicated
that RUNX2 plays an important role in regulating breast
cancer progression.
Methods
Study patients and tissues
Ninety five of the 108 breast cancer patients examined in
this study had clinicopathologically confirmed primary
ductal carcinoma of the breast, and the remaining 13
patients had non-ductal carcinoma of the breast. All
of them were diagnosed at the Tri-Service GeneralHospital, Taipei, Taiwan between October 1994 and
February 2013. Patients’ clinical information, including
cancer stage, tumor grade, estrogen receptor (ER), proges-
terone receptor (PR), HER-2/neu, recurrence and survival
status, were also noted. Recurrent breast tumors were
subjected to pathological confirmation to exclude the pos-
sibility of second primary tumors. Moreover, the cause of
death was verified from death certificate; patients whose
death was clearly documented to be due to breast cancer
were considered to have died of breast cancer, whereas
other causes of deaths were considered censored events.
Tumor and adjacent non-tumor breast tissues from pa-
tients were obtained at the time of initial surgery, and were
fully encoded to protect patient confidentiality. Clinical
specimens were utilized under a protocol approved by the
Institutional Review Board of the Human Subjects
Research Ethics Committee of Academia Sinica and Tri-
Service General Hospital, Taipei, Taiwan.
Statistical analysis
Histogram data were given as mean ± standard deviation
(SD). Comparison between the tumor and non-tumor
breast tissues was performed using Student’s t-test. We
examined whether there was any correlation between the
expression levels of the miR-10a/b and RUNX2 genes,
individually or jointly, in primary cancer tissue and
the clinicopathological features of the tumor. The goal was
to evaluate the usefulness of these three genes as prognos-
tic biomarkers for breast cancer. The expression levels of
the three genes in tumor or non-tumor tissues of different
clinicopathological feathers were described by mean ± SD
and median. The results of statistical analyses were exam-
ined against those of Student’s t-test and Wilcoxon rank-
sum test. The estimated areas under the curves (AUC) for
assessing the accuracy of prediction were calculated based
on the receiver operating characteristic (ROC) curves,
where an optimal diagnostic cutoff point was determined
to differentiate over expression of individual genes. Based
on these cutoffs, quantitative measurements of the expres-
sion levels of individual genes were converted into binary
measurements to help examine whether over expression of
these genes could be prospectively associated with breast
cancer progression using the relapse-free survival (RFS)
and overall survival (OS) as outcomes of interest. RFS was
measured as the time from surgery to recurrence or the
end of the study, and OS was defined as the time from sur-
gery to death or the end of the last follow-up for a patient.
Survival curves were plotted by using the Kaplan–Meier
method and 5-year RFS-rate and 10-year OS-rate point es-
timates with 95% confidence interval (CI) were reported.
The significance of these associations was assessed using
the log-rank test. The Cox regression model was used to
compute hazard ratios. P-value less than 0.05 were con-
sidered statistically significant. All data analyses were
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version 9.3 (SAS institute, Cary, NC, USA).
Cell cultures
MCF7 breast cancer cell line was cultured in Modified
Eagle Medium (MEM) supplemented with 10% fetal bo-
vine serum (FBS). MDA-MB-231 and MB157 breast can-
cer cell lines, U2OS osteosarcoma cell line and 293 T
embryonic kidney were cultured in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% FBS.
BT483 breast cancer cell line was cultured in Roswell
Park Memorial Institute medium (RPMI) supplemented
with 10% FBS. All cell lines were obtained from American
Type Culture Collection (ATCC, Manassas, VA, USA).
RUNX2 plasmid, RUNX2 siRNA and miRNA Oligo synthesis
and transfection
Total RNA from the osteosarcoma cell line U2OS was ex-
tracted using Trizol reagent (Invitrogen, Carlsbad, CA,
USA), and 1 μg of RNA was reverse transcribed using the
SuperScript III RT–PCR kit (Invitrogen). For cDNA clon-
ing, full-length RUNX2wt was amplified from cDNA of
the U2OS cell line using the PCR primer pair (RUNX2wt-
forward: 5′-GCTAGCATGGACTACAAAGACGATGAC
GACAAGGTGATGCGTATTCCCGTAGATCCGAG-3′)
and (RUNX2wt-reverse:5′-CTCGAGATATGGTCGCCA
AACAGATTCATCC-3′) in an amplification mixture con-
taining 1X Pfu polymerase buffer (Stratagene, La Jolla,
CA, USA), 100 μM 4dNTPs, 1.5 mM MgCl2 and 1U Pfu
polymerase (Stratagene). The samples were amplified for
35 cycles of 95°C for 1 min 30 sec, 60°C for 35 sec, and
72°C for 2 min each, preceded by a 5 min denaturation at
95°C and followed by a 10 min extension at 72°C. The
amplified cDNAs of RUNX2wt were then cloned into
pcDNA3.1 (+) vector (Invitrogen) by ligation of the
NheI – XhoI fragments to generate the pcDNA-RUNX2
expression constructs. The sequence of pcDNA-RUNX2
was confirmed by DNA sequencing.
RUNX2 siRNA (Cat. #1027020) and siRNA control
(Cat. #1027280) were guaranteed products by manu-
facturers and purchased from Qiagen (Valencia, CA,
USA). Precursor miRNA oligos (pre-miR control #1:
Cat. #AM17110, pre-has-miR-10a: Cat. #PM10787 and
pre-has-miR-10b: Cat. #PM11108) and anti-miRNA oli-
gos (anti-miR control #1: Cat. #AM17010, anti-has-miR-
10a: Cat. #AM10787 and anti-has-miR-10b-5p: Cat.
#AM11108) were guaranteed products by manufacturers
and purchased from Ambion (Austin, TX, USA).
For plasmid transfection, 4 g of pcDNA-RUNX2 con-
struct plasmid per well with 4 μl Lipofectamine 2000
(Invitrogen) was transfected into cell lines. For siRNA
transfection, 25 nM RUNX2 siRNA per well with 2 μl
Lipofectamine RNAiMax (Invitrogen) was transfected
into cell lines. For miRNA oligos transfection, 25 nMmiRNA oligos per well with 2 μl RNAiMax were trans-
fected into cell lines. For anti-miRNA oligo transfection,
15 nM anti-miRNA oligos per well with 2 μl RNAiMax
were transfected into cell lines. The experiments were
repeated three times using six-well plates.
Real-time PCR quantification of miRNA-10a/miR-10b
and RUNX2
Total RNAs were extracted from tumor and non-tumor
breast tissues for each patient or breast cancer cell lines
using Trizol reagent according to the manufacturer’s
specifications. 4 ng of total RNAs were used for quantifi-
cation of miRNAs expression, including miRNA-10a/
miR-10b and RNU6B (U6) RNA, by TaqMan RT-qPCR
kit (miRNA-10a: Cat. #000387, miRNA-10b: Cat. #002218,
and RNU6B: Cat. #001093; Applied Biosystems, Foster
City, CA, USA) according to the manufacturer’s instruc-
tions. For the quantification of mRNA of RUNX2 and
GAPDH, 1 g of total RNAs was reverse transcribed into
cDNA using the SuperScript III kit and the specific
mRNAs were detected by Power SYBR Green PCR Master
Mix (Applied Biosystems) according to the manufacturer’s
instructions. The primer sequences of RUNX2 and
GAPDH qPCR were: RUNX2 5′-AGCAAGGTTCAACG
ATCTGAGATT-3′ (forward) and 5′-AAGACGGTTATG
GTCAAGGTGAAA-3′ (reverse); GAPDH 5′-CTGCTCC
TCCTGTT CGACAGT-3′ (forward) and 5′-ACCTTCC
CCATGGTGTCTGA-3′ (reverse). The gene expression
was normalized based on threshold cycle (Ct) values of
common internal control for miRNA quantification assays,
U6 RNA, and RUNX2 quantification assays, GAPDH. The
level of RUNX2 and miR-10a/b expression were measured
using the 2-△△Ct method [27]. The results were presented
as fold change of each gene in the tumor tissue relative to
the non-tumor tissue. The RT-qPCR was performed on
the 7300 Real-Time PCR System (Applied Biosystems).
The procedures were repeated three times for all samples,
and mean values were obtained for statistical analysis.
Western blotting
Cell lysates were extracted in 0.1 M NaCl, 0.01 M
TriszHCl (pH 7.6), 1 mM EDTA (pH 8.0), 1 mg/ml
aprotinin, and 100 mg/ml PMSF, while protein con-
centration was determined by a Bio-Rad protein assay.
Protein (50 μg) was boiled at 95°C in sodium dodecyl
sulfate (SDS) sample buffer for 5 min, electrophoresed
on 7–12% SDS-PAGE gels, and transferred to polyvinyl-
difluoridine membranes. These were then incubated
overnight at 4°C with (i) rabbit monoclonal antibody
against human RUNX2 (Cell Signaling Technology,
Danvers, MA, USA; #8486; 1:250), (ii) goat polyclonal
antibody against human HOXA1 (R&D Systems Inc.,
Minneapolis, MN, USA; AF5014; 1:500), (iii) goat poly-
clonal antibody against human HOXD10 (Santa Cruz
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rabbit polyclonal antibody against human Actin (Santa
Cruz Biotechnology; sc-1615-R; 1:3000). Membranes
were washed three times for 15 min with phosphate
buffered saline (PBS) containing 0.1% Tween20 (PBST),
incubated with anti-goat or anti-rabbit secondary anti-
body (both Santa Cruz Biotechnology; 1:5000) at room
temperature for 60 min, and then washed three times
for 15 min with PBST. The signals of protein bands were
visualized using ECF western blotting kit (Amersham
Biosciences, Piscataway, NJ, USA) and detected by
Typhoon 9400 imager (Amersham Biosciences).
Cell migration and invasion assays
Cell migration and invasion were assayed using a trans-
well chamber (Millipore, Temecula, CA, USA) with or
without Matrigel (BD, Franklin Lakes, NJ, USA). 1 ml
serum free medium was added into a 24-well plate, and
a transwell chamber was placed into the well in both as-
says. The chamber was coated with 50 μl Matrigel and
incubated for 2 hours at 37°C for the invasion assay.
After transfection for 72 hours, in migration assay: cells
were trypsinized and seeded into chambers at the dens-
ity of 1 × 104 cells for MDA-MB-231 and 3 × 104 cells
for MCF7 per well; and in invasion assay: cells were 2 ×
104 cells for MDA-MB-231 and 6 × 104 cells for MCF7.
Eight hours later for migration and 24 hours later for inva-
sion in MDA-MB-231, and 12 hours later for migration
and 32 hours later for invasion in MCF7, migrated cells
remaining in the basal chamber were fixed and stained
with 10% ethanol in 1% crystal violet for 30 min and
washed three times with PBS. Non-migrated cells were re-
moved by cotton swabs. Images of the stained cells were
obtained under a phase-contrast microscope (Olympus,
Tokyo, Japan). To quantify the number of invading cells,
crystal violet-stained cells in visual fields were counted.
The experiments were repeated three times and mean
values were obtained for statistical analysis. Detailed mate-
rials and methods can be found in Additional file 1.
Results
Clinical features of breast cancer patients
It has been shown that RUNX2 plays an important role
in cell migration and invasion in breast cancer and higher
expression is associated with poor outcome [6,8,14].
Meanwhile, others have reported the contribution of miR-
10a/b to cell migration and invasion in breast cancer and
miR-10b overexpression correlates with poor prognosis
[23-26]. However, the inter-relationship between RUNX2
and miR-10a/b and their joint impact on prognosis in
breast cancer has yet to be investigated. We examined one
hundred and eight patients with histologically proven
breast cancers to delineate the relationship between the
expression of RUNX2 and miR-10a/b, and clinicaloutcomes. Their clinical and pathological features were
summarized in Table 1. The mean age was 59.2 ± 13.2 years
and the median follow up for relapsed patients and overall
survival was 54.6 and 63.2 months, respectively. The dis-
tribution of cancer stages was stage 0 (2.80%), stage I
(31.78%), stage II (42.99%) and stage III (22.43%), respect-
ively, and of the molecular subtypes was Luminal A (ER +
or PR+, Her2-) (33.33%), Luminal B (ER + or PR+, Her2+)
(35.19%), Her2 positive (ER-, PR-, Her2+) (15.74%) and
triple negative (ER-, PR-, Her2-) (15.74%), respectively.
These clinical and pathological characteristics of the breast
cancer subjects across the strata of age, hormone receptor
status, and Her2, were similar to those reported in other
breast cancer clinics in Taiwan [28-30].
The relationship between expression of RUNX2 and
miR-10a/b genes in breast cancer tumors and clinical
parameters
The expression levels of RUNX2 and miR-10a/b were
determined in tumor tissues and adjacent non-tumor tis-
sues by qPCR. As shown in Table 2, the median expres-
sion levels of RUNX2 and miR-10b were significantly
higher in tumor tissue than in non-tumor tissues by 2.16
and 1.73 fold, respectively (p < 0.0001, p < 0.0001). There
is also a trend for higher expression of miR-10a in tumor
tissues than in non-tumor part, but the difference did
not reach statistical significance (p = 0.1318). Patients
with ER- or triple negative subtypes displayed higher-
level expression of these three genes than those with
ER + or non-triple negative subtypes. Analysis of clinical
outcome revealed that patients who relapsed or died of
breast cancer showed higher expression of these three
genes than non-relapse or alive patients. On the other
hand, no significant association was found between the
expression levels of these three genes and gender, hist-
ology, stage, regional lymph node involvement or status
of PR and Her2, although there was a trend for higher
expression in patients with higher histology grade (Table 2;
Additional file 1: Table S1).
Overexpression of RUNX2 and miR-10a/b genes in tumors
as predictors of breast cancer outcome
To evaluate the prognostic significance of expression
levels of RUNX2 and miR-10a/b, we used the receiver
operating characteristic (ROC) curves based on the ex-
pression levels of RUNX2 and miR-10a/b in individual
tumor/non-tumor ratios to determine the cutoff values
defining “overexpression” of the three genes. According
to these cutoff values, the areas under the curves (AUC)
values for individual or various combinations of these
three genes were found to be significantly lower in non-
relapsed patients than in relapsed patients. However,
when comparing patients with fatal outcome to those
alive, only AUC values for miR-10b and combination of
Table 1 Clinical and pathological characteristics of breast
cancer patients
Characteristicsa N (%)
Age (mean ± SD and range) 59.2 ± 13.2 (35–102 yrs)
Gender
Male 1 (0.9%)
Female 107 (99.1%)
Histology
Ductal 95 (88.0%)
Other 13 (12.0%)
Grade
I 7 (6.6%)
II 36 (34.0%)
III 63 (59.4%)
Stage
0 3 (2.8%)
I 34 (31.8%)
II 46 (43.0%)
III 24 (22.4%)
ER
Negative 48 (44.4%)
Positive 60 (55.6%)
PR
Negative 40 (37.0%)
Positive 68 (63.0%)
Her2
Negative 53 (49.1%)
Positive 55 (50.9%)
Molecular subtype
Luminal A 36 (33.3%)
Luminal B 38 (35.3%)
ER-, PR-, Her2+ 17 (15.7%)
ER-, PR-, Her2- 17 (15.7%)
Regional lymph node involvement
No 62 (58.5%)
Yes 44 (41.5%)
Relapse
No 71 (65.7%)
Yes 37 (34.3%)
RFS duration median (range) 54.6 (1.1 ~ 100.9 months)
Outcomes
Alive 100 (92.5%)
Dead 8 (7.5%)
OS duration median (range) 63.2 (1.6 ~ 217.9 months)
ER: estrogen receptor, PR: progesterone receptor, HER2: HER2/neu, RFS: relapse
free survival, OS: overall survival.
Status of ER and PR was classified as “Positive” when ≧10% of cells were stained;
HER2 status was defined as “Positive” when Dako score was 2+ or 3 + .
aClinical characteristics according to the sixth edition of the AJCC Cancer
Staging Manual (2006).
Chang et al. Journal of Translational Medicine 2014, 12:257 Page 5 of 12
http://www.translational-medicine.com/content/12/1/257these three genes were significantly lower in alive pa-
tients than in those who died (Additional file 1: Table S2).
Accordingly, we used the cutoff values to define the status
of “overexpression” in subsequent logistic and COX re-
gression analyses to ascertain correlations between gene
expression and prognostic features. Under these cutoff
values, the frequencies of overexpression of RUNX2 and
miR-10a/b genes were significantly higher in patients who
relapsed, and that of miR-10b overexpression was higher
in patients who died (all p < 0.05). Using the same dichoto-
mized values for logistic regression analysis, the odds
ratios (ORs) for relapse were higher in patients with in-
creased mRNA or miRNA levels of these 3 individual
genes, while the OR for death was only associated with
miR-10b overexpression (all p < 0.05). Patients with no
overexpression of these three genes served as the refer-
ence group. In terms of the joint effects of overexpression
of all three genes on prognosis, the ORs were respectively
20.32 (95% confidence interval (CI) = 1.50 ~ 179.92) and
17.05 (95% CI = 1.76 ~ 165.01) for relapse and death (P <
0.05). There was a trend toward an incremental additive
effect on significantly elevated risk of relapse (OR = 2.66;
95% CI = 1.50 ~ 4.75), death (OR = 2.90; 95% CI = 1.22 ~
6.89) and regional lymph node involvement (OR = 1.51:
95% CI = 1.03 ~ 2.21), respectively, as patients carried a
greater number of overexpressed genes (P-trend < 0.05;
Table 3; Additional file 1: Table S3).The correlations between overexpression of RUNX2 and
miR-10a/b and poor clinical outcome
The correlations between overexpression of RUNX2 and
miR-10a/b, individually or jointly, and clinical outcomes
were examined by the Kaplan–Meier method of patients.
Both RFS (Figure 1) and OS (Additional file 1: Figure S1)
were significantly lower in patients with overexpression of
RUNX2 or miR-10b individually (Figure 1A, C; Additional
file 1: Figure S1 A, C). Compared to the patients with no
overexpression of these three genes, those with a greater
number of overexpressed genes (1, 2, or 3) in tumors
showed lower rates of RFS (log-rank p < 0.0001) and OS
(log-rank p = 0.0002) (Figure 1D and Additional file 1:
Figure S1D). Multivariate Cox regression analysis showed
a significant correlation between higher hazard ratios
(HRs) for relapse and greater gene signals for all three
genes individually and a correlation between higher HR
for death and expression of miR-10b (Table 4; Additional
file 1: Table S4). As to the joint effects of overexpression
of all three genes compared with no overexpression of
any of them on prognosis, the HRs were 12.37 (95% CI =
1.62 ~ 94.55) and 14.59 (95% CI = 1.66 ~ 128.24) for re-
lapse and death, respectively (P = 0.015, 0.016). The
multiple gene additive model displayed a statistically
significant HR of 2.25 for RFS (95% CI = 1.44 ~ 3.52,
Table 2 Correlation of expression of miR-10a, miR-10b and RUNX2 with clinical parameters of breast cancer patients
miR-10a miR-10b RUNX2
Variable Mean ± SD Median (Range) P valuea P valueb Mean ± SD Median (Range) P valuea P valueb Mean ± SD Median (Range) P valuea P valueb
Tissue
Non-tumor 1.00 ± 0.00 1.00 (1.00 ~ 1.00) Ref. Ref. 1.00 ± 0.00 1.00 (1.00 ~ 1.00) Ref. Ref. 1.00 ± 0.00 1.00 (1.00 ~ 1.00) Ref. Ref.
Tumor 2.02 ± 0.28 1.19 (0.01 ~ 18.57) 0.0003c 0.1318d 3.13 ± 0.42 1.73 (0.07 ~ 26.72) <0.0001c <0.0001d 522.43 ± 381.75 2.16 (0.01 ~ 37902.36) 0.1748c <0.0001d
ER
Negative 2.88 ± 0.53 1.61 (0.07 ~ 18.57) Ref. Ref. 4.32 ± 0.76 2.24 (0.08 ~ 26.72) Ref. Ref. 818.84 ± 789.26 3.64 (0.53 ~ 27902.36) Ref. Ref.
Positive 1.33 ± 0.23 0.86 (0.01 ~ 11.91) 0.0085 0.0026 2.18 ± 0.40 1.49 (0.07 ~ 20.34) 0.0148 0.0134 285.31 ± 276.77 1.43 (0.01 ~ 16612.71) 0.5260 <0.0001
Molecular subtypes
Luminal A 1.34 ± 0.25 0.84 (0.04 ~ 7.48) 0.0178 0.0012 2.16 ± 0.31 1.54 (0.11 ~ 6.68) 0.0303 0.0064 8.29 ± 6.45 1.47 (0.01 ~ 233.94) 0.8339 <0.0001
Luminal B 1.97 ± 0.41 1.35 (0.01 ~ 11.91) 0.0501 0.0305 3.22 ± 0.76 1.87 (0.07 ~ 20.34) 0.0965 0.0146 1466.29 ± 1077.31 2.02 (0.30 ~ 37902.36) 0.1846 0.0070
ER-, PR-, Her2+ 1.96 ± 1.06 0.88 (0.07 ~ 18.57) 0.2294 0.0047 2.34 ± 0.98 0.92 (0.08 ~ 15.79) 0.0637 0.0067 14.06 ± 7.34 2.72 (0.54 ~ 127.12) 0.5935 0.2280
ER-, PR-, Her2- 3.63 ± 0.85 2.10 (0.37 ~ 13.55) Ref. Ref. 5.80 ± 1.51 5.49 (0.33 ~ 26.72) Ref. Ref. 9.78 ± 2.89 5.94 (1.17 ~ 50.56) Ref. Ref.
Relapse
No 1.83 ± 0.34 1.02 (0.04 ~ 18.57) Ref. Ref. 2.46 ± 0.40 1.36 (0.07 ~ 20.34) Ref. Ref. 5.53 ± 1.85 1.88 (0.26 ~ 127.12) Ref. Ref.
Yes 2.37 ± 0.48 1.35 (0.01 ~ 13.55) 0.3753 0.1002 4.42 ± 0.91 2.04 (0.08 ~ 26.72) 0.0578 0.0171 1514.33 ± 1105.78 3.46 (0.01 ~ 37902.36) 0.1809 0.0268
Outcomes
Alive 1.86 ± 0.27 1.10 (0.01 ~ 18.57) Ref. Ref. 2.92 ± 0.42 1.55 (0.07 ~ 26.72) Ref. Ref. 184.40 ± 166.24 2.07 (0.01 ~ 16612.71) Ref. Ref.
Dead 3.96 ± 1.32 2.03 (0.84 ~ 10.56) 0.0450 0.0270 5.77 ± 1.84 5.14 (1.91 ~ 17.88) 0.0723 0.0099 4747.89 ± 4736.36 7.02 (0.30 ~ 37902.36) 0.3676 0.1017
ER: estrogen receptor, PR: progesterone receptor, HER2: HER2/neu, Ref.: reference group.
The expression level of the indicated gene in tumor tissue as determined by qPCR was normalized to that of adjacent non-tumor tissue of the same patient (2-△△Ct) (see Methods for details).
aP value for independent t-test.
bP value for Wilcoxon rank-sum test.
cP value for paired t-test.
dP value for Wilcoxon signed-rank test.
Bold face: statistical significant (P value < 0.05).
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Table 3 The relationship between overexpression of individual gene or joint effects of miR-10a, miR-10b, and RUNX2
with prognosis in breast cancer patients
Relapse
No Yes
Variable Number (%) Number (%) P-value OR 95% CI P value
miR-10a 0.0424
≦0.53 27 (79.4%) 7 (20.6%) 1.00
>0.53 44 (59.5%) 30 (40.5%) 2.83 1.05 ~ 7.68 0.0407
miR-10b 0.0043
≦0.67 24 (88.9%) 3 (11.1%) 1.00
>0.67 47 (58.0%) 34 (42.0%) 5.37 1.46 ~ 19.81 0.0116
RUNX2 0.0037
≦3.05 51 (76.1%) 16 (23.9%) 1.00
>3.05 20 (48.8%) 21 (51.2%) 3.55 1.47 ~ 8.58 0.0048
Number of overexpressing genes 0.0021
0 16 (94.9%) 1 ( 5.8%) 1.00
1 11 (73.3%) 4 (26.7%) 3.30 0.30 ~ 36.29 0.3288
2 32 (68.1%) 15 (31.9%) 6.01 0.71 ~ 50.83 0.0996
3 12 (41.4%) 17 (58.6%) 20.32 2.30 ~ 179.92 0.0068
Additive model of gene overexpression 2.66 1.50 ~ 4.75 0.0009
OR: odds ratio, CI: confidence interval, Gene overexpression: the expression level of an individual gene in tumor tissue normalized to adjacent non-tumor tissue
from the same patient was categorized as “overexpression” by using the cutoff value determined from the ROC curve.
ORs and 95% CIs were estimated in the logistic regression model, in which a group of dummy variables was used to represent different groups of patients
showing different numbers of overexpressing genes.
Bold face: statistical significant (P value < 0.05).
Figure 1 Prognostic significance of increased expression levels of RUNX2, miR-10a or miR-10b in breast cancer patients. Kaplan-Meier
statistical analyses were conducted to examine the association between relapse-free survival and the expression of RUNX2 (A), miR-10a (B) or
miR-10b (C), and the number of overexpressed genes (D) in all patients.
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Table 4 Cox regression model analyses of the gene
expression levels in association with RFS of breast cancer
patients
RFS
Variable HR 95% CI P value
miR-10a > 0.53 V.S miR-10a≦0.53 2.31 1.00 ~ 5.32 0.0503
miR-10b > 0.67 V.S miR-10b≦0.67 3.96 1.21 ~ 12.98 0.0231
RUNX2 > 3.05 V.S RUNX2≦3.05 3.02 1.50 ~ 6.07 0.0020
Number of overexpressing genes
0 1.00
1 2.80 0.30 ~ 25.77 0.3642
2 4.99 0.65 ~ 38.12 0.1212
3 12.37 1.62 ~ 94.55 0.0153
Additive model of gene
overexpression
2.25 1.44 ~ 3.52 0.0004
Adjusted for age.
RFS: relapse-free survival, HR: Hazard ratio, CI: confidence interval, Gene
overexpression: the expression level of an individual gene in tumor tissue
normalized to adjacent non-tumor tissue from the same patient was categorized
as “overexpression” by using the cutoff value determined from the ROC curve.
Bold face: statistical significant (P value < 0.05).
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P-trend = 0.0125).
Suppression of RUNX2 decreased miR-10a/b expression
and impaired cell migration and invasion ability
In view of our findings of significant correlations
among RUNX2 or miR-10a/b and relapse or death, we
next investigated the inter-relationship of these 3 genes
in breast cancer cell lines in vitro. Using qPCR analysis,
we determined the expression levels of RUNX2 and
miR-10a/b in 4 breast cancer cell lines. As shown in
Figure 2A, MDA-MB-231, the invasive estrogen receptor
negative (ER-) cell line, showed the highest expression
levels of all these three molecules. Since MDA-MB-231
cells expressed very little Twist [31,32], which is reported
to upregulate miR-10b [26] and since RUNX2 is involved
in transcriptional activities of Twist [33], we explored the
possible regulation of miR-10a/b by RUNX2. Silencing of
RUNX2 by siRNA transfection of MDA-MB-231 cell line
to 24% (p < 0.0001) of control resulted in a significant
decrease in expression of miR-10a and miR-10b to 52%
(p = 0.0349) and 51% (p < 0.0001), respectively (Figure 2B).
Consistent with this, HOXA1 and HOXD10 are puta-
tive targets for miR-10a/b in Garzon et al. 2006 [34],
suppression or overexpression of miR-10a/b increased
or decreased HOXA1/HOXD10 protein expression,
respectively, in breast cancer cell lines explained in
Additional file 1: Figure S2, escalated in the silenced
RUNX2 cells by 3.86 and 2.33 fold, respectively (Figure 2C).
In line with the increased HOXA1 and HOXD10, mi-
gration and invasion ability of MDA-MB-231 cells
were significantly reduced to 21% (p = 0.0035) and 29%(p = 0.0029), respectively. (Figure 2D, E). Thus, suppres-
sion of RUNX2 reduced miR-10a/b expression, and
thereby impairing breast cancer cell motility.
Overexpression of RUNX2 induced transcription of
miR-10a/b and promoted cell migration and invasion
In order to clarify the relationship between RUNX2 and
miR-10a/b, RUNX2 was overexpressed in high and low
RUNX2 expressing breast cancer cell lines, MDA-MB-
231 and MCF7 (Figure 3A, B). RUNX2 increased the
transcription of miR-10a by 1.61 fold (p = 0.0079) and
that of miR-10b by 1.60 fold (p < 0.0001) in MCF7 cells
and increased only the expression of miR-10b by 1.52
fold (p = 0.0413) in MDA-MB-231 cells. Consistently,
protein levels of HOXA1 and HOXD10 markedly de-
clined to 0.15 and 0.09 fold, respectively, in RUNX2
overexpressing MCF7 cells, but only slightly decreased
to 0.91 and 0.71 fold in MDA-MB-231 cells (Figure 3C).
Functional assay showed that cell migration and invasion
were significantly enhanced in RUNX2 overexpressing
MDA-MB-231 (1.74 fold, p = 0.0315 and 2.51 fold, p =
0.0016, for migration and invasion, respectively) and
MCF7 cells (2.96 fold, p = 0.0143 and 4.95 fold, p = 0.0018,
respectively) (Figure 3D, E, F, G). Thus, overexpression of
RUNX2 upregulated miR-10a/b expression, thereby pro-
moting breast cancer cell motility.
To sum up, these findings suggest that RUNX2 plays
an important role in controlling breast cancer cell motil-
ity through regulation of miR-10a/b expression, and
overexpression of these three genes has poor prognosis.
Discussion
Metastasis is the major cause of mortality in cancer and
affects the clinical progression of cancer patients [35]. In
this study, primary breast tumor tissues were found to
have higher expression levels of RUNX2 and miR-10a/b
than adjacent non-tumor tissue, and overexpression in
any of these three genes was significantly associated with
poor clinical outcome.
Recently, Ma et al. has shown that the transcription
factor Twist regulates the expression of miR-10b, which
inhibits HOXD10 protein synthesis, thereby permitting
the production of RHOC proteins and activating migra-
tion and invasion of breast cancer cells. Analyses of clin-
ical specimens also indicate that miR-10b is highly
expressed in not only metastatic breast cancer [26], but
also early stage breast cancer [25]. However, as sug-
gested in another study, in early-stage breast cancer pa-
tients, the expression of miR-10b appears to show no
significant association with the development of distant
metastases, recurrence-free survival, distant-relapse-free
survival, or breast-cancer-specific survival [36]. In this
study, we showed that RUNX2 upregulated miR-10a/b
and promoted breast cancer cell migration and invasion.
Figure 2 RUNX2 silencing reduced the expression of miR-10a and miR-10b and inhibited cell migration and invasion. (A) Expression level of
miR-10a and miR-10b in breast cancer cell lines were analyzed by qPCR analysis and normalized to U6 snRNA expression. (B) MDA-MB-231 cells were
transfected with 25 μM control siRNA or RUNX2 siRNA for 72 hours. RUNX2, miR-10a or miR-10b expression levels were determined by qPCR analysis.
(C) Expression levels of RUNX2, HOXA1 and HOXD10 proteins were assessed by Western blot analysis and normalized to actin. (D) Cell migration and
invasion ability were assessed by Transwell assay or Matrigel assay, respectively as described in Material and Methods. Black line: 20 μl, Red line: 100 μl
(E) The quantification result was based on three independent experiments. *: p < 0.05, t-test.
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role in cell motility, similar to miR-10b [26], thus pro-
viding an additional mechanism in regulating breast can-
cer metastasis and invasion.
We found that, the expression of RUNX2 and miR-
10a/b in ER- and triple negative breast cancer was
higher than in ER + breast cancer. This observation may
be related to the intricate interactions among estrogen,
estrogen receptor alpha (ERα) and RUNX2, which is of
crucial importance in osteoporosis and breast cancer.
ERα can form a complex with RUNX2 to affect the cap-
ability of RUNX2 in transcribing downstream genes [37].
RUNX2 regulates the expression of ERα by interacting
with its F promoter, one of the multiple promoters of
the human ERα gene [33]. Also to be noted is that estro-
gen may also regulate the expression and activation of
RUNX2 through various signal transduction pathways,
notably the estrogen-transforming growth factor-beta
(TGFβ) pathway [38], the Wnt pathway [39], the Fas/FasLigand pathway [40], and the nuclear factor-kappaB
(NFκB) pathway [41]. Estrogen, ER and RUNX2 work to
mutually regulate their expression and activation. This
may help to explain the lower expression of RUNX2 in
ER + breast cancer than ER- tumors.
We illustrated the regulation of the expression of miR-
10a/b by RUNX2 in breast cancer cells. Several putative
RUNX2 transcription factor binding sites were found at
the proximal sequences preceding pre-miR-10a/b, based
on website software PROMO analysis (http://alggen.lsi.
upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=
TF_8.3) [42-44]. Several different reporter constructs
that carried putative RUNX2 binding sites within 15 k/
24 k upstream of pre-miR-10a/b, respectively, were gen-
erated (Additional file 1: Table S5). We then compared
the ability of RUNX2 to promote the transcription of re-
porter constructs carrying the RUNX2 sites. Unfortunately,
RUNX2 failed to enhance the transcription of the miR-
10a/b promoter regions that we cloned (Additional file 1:
Figure 3 Overexpression of RUNX2 induced expression of miR-10a and miR-10b and promoted cell migration and invasion.
(A, B) MDA-MB-231 or MCF7 cells were transfected with 4 μg control pcDNA3.1 vector or pcDNA-RUNX2 plasmid for 72 hours. RUNX2, miR-10a
or miR-10b expression levels were analyzed by qPCR. (C) RUNX2, HOXA1 and HOXD10 protein levels were assessed by Western blot analysis and
normalized to actin. (D, E) Cell migration and invasion ability were assessed by Transwell assay or Matrigel assay, respectively. Black line: 20 μl,
Red line: 100 μl (F, G). The quantification result was based on three independent experiments. *: p < 0.05, t-test.
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tion of miR-10a/b by RUNX2 will be further pursued in
the future. Moreover, the RUNX2 cofactors, including
STAT1, Twist, YAP or ERα protein [37,45], have been re-
ported to play important roles in RUNX2 transcription
ability and regulation of downstream gene expression.
These RUNX2 cofactors will be incorporated into future
studies to further clarify how RUNX2 regulates miR-10a/b
transcription.
Conclusion
Through in vitro experiments, our study demonstrates
the impact of RUNX2 on breast cancer migration and
invasion and its regulation of miR-10a/b expression. Im-
portantly, our clinical-laboratory correlative analyses in-
dicate that breast cancer patients with higher expression
of RUNX2 and miR-10a/b – either individually or jointly –
tend to suffer a greater risk of recurrence or death. There-
fore, the three genes – RUNX2, miR-10a, and miR-10b –
are deemed valuable markers for prognostication of breast
cancer patients.Additional file
Additional file 1: Table S1. Correlative analysis of expression of
miR-10a, miR-10b and RUNX2 with clinical parameters of breast cancer
patients. Table S2. ROC analysis of expression of miR-10a, miR-10b,
RUNX2 for predicting outcome in breast cancer patients. Table S3. The
relationship between overexpression of individual gene or joint effects of
miR-10a, miR-10b, and RUNX2 with prognosis in breast cancer patients.
Table S4. Cox regression model analyses of the gene expression regarding
OS of breast cancer patients. Table S5. Predicted RUNX2 binding sites at
proximal sequences preceding pre- miR-10a and pre-miR-10b. Figure S1.
Prognostic significance of increased expression levels of RUNX2, miR-10a or
miR-10b in breast cancer patients. Figure S2. Target gene expression of
suppression or overexpression miR-10a and miR-10b. Figure S3. Luciferase
reporter assay of putative RUNX2 target genes.
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